Eli Lilly Is Suing Sellers of Its Experimental Weight-Loss Drug on the Black Market
Eli Lilly filed six lawsuits on August 12, 2026, against U.S. companies it says are selling retatrutide — an experimental weight-loss drug — illegally on the black market. The defendants include Aesthetic Envy, Astra, and Legendary, according to Reuters. The targets include compounding pharmacies (which make custom versions of drugs), medical spas, and online sellers.
Lilly also called on online platforms, payment companies, and regulators to act against the illegal retatrutide trade, per a company press release. Patients have experienced various harms after taking black-market retatrutide products sold online, the company stated. This is not Lilly's first move of this kind. In June 2024, the company filed legal actions against med-spas and online pharmacies advertising compounded pill or oral versions of its medicines, and it previously warned about patient safety risks tied to compounded tirzepatide mixed with vitamin B12.
Retatrutide (also designated LY3437943) is an experimental drug that targets three receptors in the body — GLP-1, GIP, and glucagon — all of which help regulate metabolism and appetite. Think of it as flipping three switches at once that together reduce hunger and increase calorie burning. Lilly is developing the drug for obesity. It is not approved by the FDA. Any retatrutide sold outside a clinical trial is, by definition, unapproved and of unverified quality.
The clinical data driving black-market demand is substantial. In Lilly's Phase 2 trial, retatrutide achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight, Lilly announced on May 21, 2026. At the 12 mg dose over 80 weeks, participants lost an average of 70.3 lbs, or 28.3% of body weight. 45.3% of participants on that dose achieved weight loss of at least 30%. Separately, in the TRIUMPH-4 trial, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of body weight at 68 weeks, Lilly reported in December 2025.
Lilly is also conducting an ongoing study examining how retatrutide maintains body weight loss in participants with obesity.
The broader context here is a gray-market ecosystem that grew rapidly around similar weight-loss drugs during recent shortages of tirzepatide and semaglutide. When drugs are in short supply, some pharmacies legally make custom versions. But some sellers go further, offering unapproved or experimental drugs outside that legal framework. Now that retatrutide is showing strong results in trials, unauthorized sellers are capitalizing on the headlines before the drug has passed FDA review. The fact that patients are already reporting harms from illicit retatrutide points to the quality-control risks of drugs made outside FDA oversight. Lilly's strategy of pressuring payment companies and online platforms, not just the sellers, is designed to choke off distribution channels rather than chase individual sellers one by one.
For investors, the key questions are straightforward. First, whether the FDA follows Lilly's private lawsuits with its own enforcement; the agency has historically acted on compounded and counterfeit drugs only after manufacturer pressure builds. Second, whether the lawsuits and warnings actually reduce illicit supply, or whether the market simply moves to new sellers and platforms. Third, whether any adverse events tied to black-market retatrutide feed back into the regulatory review of the legitimate drug, though there is no sign of that yet.
The scale of the problem is hard to measure. Lilly has not disclosed how many patients it believes purchased illicit retatrutide, nor has it detailed the specific harms beyond calling them "various." The six lawsuits target named defendants, but the company's appeal to platforms and payment processors suggests the problem extends well beyond those six entities.
